Stifel Nicolaus Downgrades VistaGen Therapeutics (NASDAQ:VTGN) to Hold

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. They presently have a $1.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 35.14% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, October 8th. William Blair reiterated an “outperform” rating on shares of VistaGen Therapeutics in a research report on Tuesday, October 21st. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.74 on Wednesday. VistaGen Therapeutics has a 52-week low of $0.73 and a 52-week high of $5.14. The company has a fifty day moving average of $4.06 and a 200-day moving average of $3.29. The stock has a market capitalization of $29.22 million, a price-to-earnings ratio of -0.39 and a beta of 0.56.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.16 million. On average, equities research analysts forecast that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC lifted its holdings in VistaGen Therapeutics by 246.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after buying an additional 299,304 shares during the period. Two Sigma Investments LP raised its holdings in shares of VistaGen Therapeutics by 223.5% during the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after acquiring an additional 199,958 shares in the last quarter. Jane Street Group LLC purchased a new stake in VistaGen Therapeutics in the second quarter worth $190,000. Stempoint Capital LP boosted its holdings in VistaGen Therapeutics by 2.0% in the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after acquiring an additional 46,700 shares in the last quarter. Finally, AdvisorShares Investments LLC increased its position in VistaGen Therapeutics by 27.7% during the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after purchasing an additional 44,000 shares during the period. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.